# A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )

> **NCT07526974** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Caliway Biopharmaceuticals Co., Ltd.** · enrollment: 320 (estimated)

## Conditions studied

- Subcutaneous Fat

## Interventions

- **DRUG:** CBL-514 Injection
- **DRUG:** 0.9% Sodium Chloride

## Key facts

- **NCT ID:** NCT07526974
- **Lead sponsor:** Caliway Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2027-08
- **Final completion:** 2027-10
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07526974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07526974, "A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07526974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*